@article{21579,
  keywords = {Adult, Erythema Nodosum, Etanercept, Female, Humans, Immunoglobulin G, Immunologic Factors, Leprosy, lepromatous, Receptors, Tumor Necrosis Factor, Treatment Outcome, Tumor Necrosis Factor-alpha},
  author = {Ramien M and Wong A and Keystone JS},
  title = {Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept.},
  abstract = {<p>Erythema nodosum leprosum (ENL), or type II reaction, is a common complication of lepromatous leprosy that can cause significant patient debility. First-line therapy includes prednisone and thalidomide, with clofazimine reserved for patients who do not respond to first-line treatment. We present the case of a 33-year-old woman with ENL that failed to respond adequately to conventional therapy over a 6-year period. Because of the severe nature of her disease and the adverse effects of therapy that she experienced, a trial of etanercept was undertaken, which led to full resolution of her ENL. The rationale behind our choice of therapy and its future implications are discussed.</p>},
  year = {2011},
  journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  volume = {52},
  pages = {e133-5},
  month = {2011 Mar 01},
  issn = {1537-6591},
  url = {http://cid.oxfordjournals.org/content/52/5/e133.full.pdf+html},
  doi = {10.1093/cid/ciq213},
  language = {eng},
}